文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤患者经免疫检查点抑制剂获得长期疾病控制后的结局

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
PubMed 文献 · Eur J Cancer · 2024-12-09

该回顾性队列纳入567例经免疫检查点抑制剂(ICI)治疗获得长期疾病控制的晚期黑色素瘤患者,中位随访7.1年。3年内无进展者504例(89%)为队列1,3年内进展但未更换系统治疗者63例(11.1%)为队列2。3年后进展在队列1为39例(7.7%),队列2为14例(22%);随访期间死亡32例(5.6%),其中黑色素瘤相关死亡8例(1.4%)。

要点

  • 长期疾病控制定义为ICI开始后3年内无需后续系统治疗。
  • 3年后进展的预测因素为最佳影像学非完全缓解(non-CR)及3年内曾进展。
  • 该人群后续进展与死亡风险低,作者认为相当比例长期ICI应答者可能已治愈。

核心结论

  • 在经ICI获得长期疾病控制的晚期黑色素瘤患者中,后续疾病进展和死亡的风险低,作者认为相当比例长期ICI应答者可能已治愈,并可能为随访频率和时长提供参考。

研究设计与样本

  • 回顾性识别接受ICI治疗晚期黑色素瘤并获得长期疾病控制的患者,长期疾病控制定义为ICI开始后3年内无需后续系统治疗,共567例,中位随访7.1年。

主要发现

  • 567例中504例(89%)3年内无疾病进展(队列1),63例(11.1%)3年内进展但未更换系统治疗(队列2)。
  • 3年后后续进展在队列1为39例(7.7%),在队列2为14例(22%)。
  • 3年后进展的预测因素为最佳影像学非完全缓解(non-CR)及3年内曾进展。
  • 随访期间死亡32例(5.6%),其中黑色素瘤相关死亡8例(1.4%),队列1为6例(1.2%),队列2为2例(3.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite clinical trial data, little is known about the risk, character, and clinical outcome of late recurrences after ICI. This study aimed to explore the disease outcomes and survival in a cohort of patients with long-term responses to ICI. We retrospectively identified patients treated with ICI for advanced melanoma with long-term disease control, defined as not requiring a subsequent line of systemic therapy within 3 years of ICI commencement. We analysed disease characteristics, treatment, toxicity, recurrence patterns, management, and outcomes. A total of 567 patients were identified with a median follow-up of 7.1 years: 504 (89 %) without disease progression within 3 years (cohort 1) and 63 (11.1 %) with disease progression within 3 years managed without a change in systemic therapy (cohort 2). Subsequent progression after 3 years occurred for 39 (7.7 %) patients in cohort 1, compared to 14 (22 %) in cohort 2. Predictors for late progression after 3 years were a non-complete radiological response (CR) best response and prior progression within 3 years. Thirty-two patients (5.6 %) died during follow-up, 8 (1.4 %) from melanoma, 6 (1.2 %) from cohort 1 and 2 (3.2 %) from cohort 2. In this population of patients with advanced melanoma with long-term disease control from ICI, the risk of subsequent disease progression and death was low. This suggests that a significant proportion of long-term ICI responders are likely cured and may inform the frequency and duration of follow-up.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Handel EE, McKeown J, Wei J, et al. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma. Eur J Cancer. 2024. PMID: 39667250. doi:10.1016/j.ejca.2024.115171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。